Member Info for PM2022

Explain how this is true then? If the sub-license was due to be signed at the end of 2023 but delayed slightly due to the merger then they would have the cash? Also the official article confirmed TRX had strong access to cash.

“We believe TheoremRx has strong access to capital and a robust pipeline of compounds addressing high-demand unmet therapeutic areas with near-term inflection points. Its project portfolio is also pre-selected for high upside, with minimal time and cost to reach key monetization milestones. By combining the respective strengths of our two companies’ platforms, we believe that we can help critical new biopharma treatments advance through the clinical trial process while creating significant value for shareholders.”

The sub-license contains provisions for upfront and early-stage milestone payment and will release the immediate payment for work already conducted under the previously announced service agreement as well as a commitment for future service provision.

Also it appears TRX has compounds ready for commercialization soon so I stick to the facts not what some derampers are saying:

Digging Deeper: EUDA Health was founded in 2019 in Singapore as a technology-based provider of healthcare services. It went public on the Nasdaq last year using a special purpose acquisition company (SPAC). EUDA said TheoremRx has access to a “robust pipeline of compounds” to treat various medical conditions. TheoremRx Chairman Dr. Kenneth Sorensen added that his company’s treatments under development have an addressable market of $16 billion, and that some could be ready for commercialization as soon as the second half of next year. The two companies signed a letter of intent on Oct. 4, and have 30 days after that to negotiate a final agreement.

Pure speculation and given you lost all your money on 4D and have nothing left to invest not exactly surprising.

One can also say the LOI would change and they could get 4/5 million upfront payments. The basis of the merger is that TRX has access to significant cash and has a strong pipeline as stated in the article.

Go based on facts. The deadline was for DD not for an RNS to be released given you cannot even read then why listen to the rest. Had it failed they would have to inform us so it has passed that stage. Even an extension would have required notification.

That is what a phase 2A trial would produce anyway. The aim is to complete the larger phase 2 trials and that would give the milestone and upfront payments. You can't say if you got a preclinical deal worth 100s million that it has not been tested on humans for instance as that is not the aim at the stage.

We know the reasons why TRX were picked as it has been discussed 100s of times.

Apparently TRX has a few compounds that could be commercialised later this year with a market worth over 15 billion.

Potentially significant as far as fund raising for future 201 trails is concerned. That would also benefit EUDA allowing for a higher share price and making it easier to raise funds . TRX can also benefit financially in a big way if this is the case as the exit strategy appears to be to eventually sub-license each compound to large pharma companies for big bucks.

EUDA were low on cash so it makes sense to do what they did.

A lawyer, for example, could charge anywhere from $25,000 to $100,000 or even more to help you navigate through this process. It's also recommended that you hire an accounting firm to go over the financial statements of both companies, which will add another $25,000 to $75,000 to your expenses on average. Investment banking fees will also need to be accounted for, and they change depending on the situation, but as a rule of thumb you can typically expect this to come out to about 3% to 10% of the overall value of the transaction.

Then implementation of strategy following the merger:

Rebranding, restructure such as hiring specialist staff, costs with expansion perhaps such as new offices etc. Here not sure how the clinical trials will work but it will cost EUDA money one way or the other as well.

Therefore the extra cash would have been for this as they anticipate this will complete therefore additional expenses required for growth purposes.

Ask yourself why this statement is made by TheoremRX if the merger was to fail and why was it made public at the time?

Promising Horizons: The next 18-24 months brings with it exciting milestones for us and we're excited about the potential benefits for our patient community.

The due diligence must have passed as we had no negative announcement within the timeline and this would have been necessary even if it was delayed further. The next stages are legal, negotiations and any approvals but this should not take long as DD is the longest and most time consuming stage of M and A.

The typical steps in M and A are:

Decision to acquire companies as inorganic growth

Criteria for acquiring a company

Company search and selection

Planning

Evaluation

Negotiation

Due Diligence ( The timelines in the deadline was for this only so likely has passed)

Contract of acquisition

Transaction Financing

Closing

Post-Closing (Much more important than it may seem)

If 201 completes we may never need a placing for at least a few years. By then we will hopefully have a deal for one of the pre clinical projects giving decent cash. 6P is a strong buy.

Anyway I think the 833,333 buy came from Stella. She purchased 333 333 in the placing so something about those odd numbers with lots of 3s even though it was for £50k which was likely rounded up. It could have been like 832 000 rather than 833 333.

All that matters is the market cap. At 50p our market cap will likely be about 65 million. That is possible with 201, 401 complete plus a strategy that keeps progressing with new compounds and lab contracts coming in generating revenue to eventually attract larger investors causing a strong rise.

Should be August 2023.

WCP,

It is not over yet.

Example Oxford Biomedical did a placing at 11p in November and after news 2 months later went to around 50p. Almost 50 million new shares.

I think the 201 deal will be transformational news as it will us decent cash and potential milestone payments. 2-3 years cash plus further lab revenue to come and by then we should get more deals.

Oxford, UK - 2 AUGUST 2023 - Oxford BioDynamics PLC (AIM: OBD, "OBD", the "Company" and, together with its subsidiaries, the "Group"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, is pleased to announce that it has successfully raised gross proceeds of £5.6m pursuant to a placing, conducted via an accelerated bookbuild process (the "Placing") and through direct subscriptions (the "Subscription").

Conditionally, in aggregate, 48,120,790 new ordinary shares of 1p ("Ordinary Shares") each in the Company will therefore be issued pursuant to the Placing (the "Placing Shares") at an issue price of 11p per new Ordinary Share ("Issue Price"). The Placing comprised both a General Placing and a VCT/EIS Placing. Subscribers have conditionally subscribed for, in aggregate, 2,528,634 new Ordinary Shares (the "Subscription Shares") at the Issue Price.

In addition, retail investors are able to participate via the PrimaryBid platform (the "PrimaryBid Offer", and together with the Placing and the Subscription, the "Fundraising"). The PrimaryBid Offer remains open. Further details on the results of the PrimaryBid Offer will be announced separately.

The Placing Shares and Subscription Shares represent approximately 25.7 per cent. of the Company's issued ordinary share capital as enlarged by the Placing and Subscription.

Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the Placing.

Admission and settlement

An application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will become effective and dealings in the VCT/EIS Placing Shares will commence on 21 August 2023 and dealings in the General Placing Shares, the Subscription Shares and the PrimaryBid Shares will commence on 22 August 2023, subject to the passing of the Resolutions at the General Meeting. The Placing Shares being issued pursuant to the Placing, the Subscription Shares being issued pursuant to the Subscription and the PrimaryBid Shares being issued pursuant to the PrimaryBid Offer will, on Admission, rank in full for all dividends and other distributions declared, made or paid on the Ordinary Shares after Admission and will otherwise rank pari passu in all respects with the Existing Ordinary Shares.

The correct outcome as you cannot buy and build all the way down without adding value then give yourself free options each time.

I would give them another chance until the summer as we don't want to lose everything we have including the potential of 201 being complete soon and further lab contracts.

If they deliver they can get the options at a later date. Likely the grass is not greener on the other side in this case and replacing them with a couple of useless individuals is not the way forward. Unless Adam puts himself forward that is.

Adam was right when he said they should focus on getting one decent early deal first before building the company the way they are.

You cannot build a company at a lower price each time without destroying shareholder value as you will be burning up the cash buying assets and funding those assets causing more placings at lower prices. They purchased the lab and Imogen but it added zero value to existing holders and continues to burn more cash. It may come good one day but we would be left with nothing. Had they not spent all that money on Imogen including staff costs for Gareth we would still have another 2/3 months cash at a critical time and therefore a potential placing much higher price after 201.

When you buy assets it should add value for existing holders not dilute them massively to the point they see no returns.

Unless 201 comes good in the next 4 weeks then we need some changes. I don't like the negative approach to placings as well. This could have been done at 10p or more comfortably over the last few weeks imo. We need a fresh start where the focus is on progressing what we have until something comes good and not wasting more money and a BOD that can work with Adam at board level.

I just get the impression they want to keep building rather than focussing on adding value to current holders therefore I suggest some changes at a later date unless they deliver on 201 soon.

201 is still on. I never said no placing, it was always a possibility. Just that the price is lower than what we would have liked.

A normal CEO would have done it after good news but it never seems to happen with Val.

Porky was not right as he was calling 1p or 2p or no support. 6p is 500% higher and 201 will still likely get done and cash will come when the sub licence is signed. It was always going to be tight.

I feel the rise will be stronger with cash in the bank as it eliminates the fears of a placing. With lab revenue we will likely have 2 years cash and with 201 signed 3 years cash. By then CLX deal will be completed or one of the other compounds giving a large upfront payment so likely this will be the last placing ever. If Adam was on the board I would be more confident of that.

I don't support them but if people can find a CEO that is prepared to buy big or invest a fair amount then let us know.

I am not sure if it will take us backwards. It will probably take 6 months just to understand what direction to go. If they do clinical trials and change strategy then you will end up with consolidations.

I feel the real solution here is for Adam to be more involved at board level. Shareholders need someone that wants the SP to do well and I am not sure about these lot but again I think a replacement will most likely not solve this problem.

All placings have been badly managed but with lab revenue they should have more than 2 years of cash so no doubt we will still get to decent levels given we are massively undervalued. 6P will no doubt be rewarding for those that participate. Possibly no placing ever again as a deal for CLX will mean this will be the last placing ever.

I feel Adam should resign from the APTA board and join the VAL board. We need a real shareholder like Adam on the BOD. They messed up last time on 201 and again.

Surely that should mean NYCT will also go bust. Best to watch that stock because when Porky is positive stocks go bust when negative they fly. Maybe NYCT is a good short.

Whilst we all focus on 201, what if Suzy and her team are negotiating a deal for CLX. It was stated it was an option they would look at.

So a potential 20 million upfront payment and milestone of well over 200 million where would we open then. 100p opening price. Who remembers when Synairgen dropped from 200p to 10p on open after failed trial results.

Well if 201 goes through and completes then anything is possible or if CLX gets a deal this could open above 50p.

The market cap is too low here and low enough for most to be caught out when big news comes.

Update due soon. It will be interesting.

I understand we are due a quarterly update from Val before Christmas but I doubt they can comment on the merger without news being released first unless they simply say they still expect the sublicense to be completed this year.

I think we will get news from EUDA today and maybe the update from Val tomorrow or Friday. Could also be tomorrow with the update on Friday.

Well yes Val has plenty of promising compounds and more to come. If TRX doesn't impress then they will never get a sniff of anything. All about building relationships and if it works both ways then it gets done. TRX investors might be happy with the medium term to long term and Val may want more shorter term capital from the deal.

Alternatively they take a stake in the company at 15p or above for further cash.

As long as we get it over the line but yes I think Val will push for different terms given SP has dropped and cash is lower than what it was 2 years ago so circumstances have changed due to the delays. If they say no then it could even be mutually beneficial to both parties so for example they can drop the $61million to $55 million for an extra 1.5 million upfront cash on top of what was agreed plus royalties. Works both ways and who knows.

It is just a LOI and agreement needs to be finalised for the merger. Plus terms can change as non binding so they have to agree before merger completes. What if the merger completes and Val or others say no......